BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Neobe Therapeutics Raises US$6.8 Million to Advance Engineered Bacteria for Solid Tumours

Neobe has secured a seed round of US$6.8 million (£5 million) to accelerate the development of engineered bacteria that break down the physical...

November 11, 2026 | News

Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery

Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...

November 11, 2026 | News

Sanyou Bio Secures Nearly RMB 100 Million in Series C to Advance AI-Driven Drug R&D

Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") rece...

November 11, 2026 | News

Ribo Files EU Phase I Trial Application for Dual-Target siRNA Therapy SR122

Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase...

November 11, 2026 | News

Innovent’s Tafolecimab Monotherapy Cuts LDL Cholesterol by More Than 60% in Phase 3 Trial

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks ...

November 10, 2026 | News

China Accepts Lynk Pharmaceuticals’ Zemprocitinib Filing for Rheumatoid Arthritis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

November 09, 2026 | News

OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy

33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...

November 09, 2026 | News

Illumina Selected to Sequence 450,000 Genomes for Singapore’s SG-INSIGHT Study

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be i...

November 06, 2026 | News

Akeso’s Ivonescimab Plus Chemotherapy Granted Priority Review in China for First-Line Biliary Tract Cancer

Akeso, Inc. announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer...

November 06, 2026 | News

Telix Joins Thera4Care to Advance FAP-Targeted Theranostics Research

Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe Telix's fibroblast activation...

November 06, 2026 | News

NUHS, Singtel and Ericsson Expand Partnership to Advance AI-Enabled Healthcare and 6G Research

Extended collaboration will accelerate research and development in advanced connectivity and emerging 5G Advanced & future 6G tec...

November 05, 2026 | News

Zuellig Pharma Acquires Hangzhou Facility to Strengthen Clinical Trial Supply in China

The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across Chi...

November 05, 2026 | News

Minghui Signs Japan Licensing Deal With ASKA Worth Up to $440 Million for Thyroid Eye Disease Therapy

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement fo...

November 05, 2026 | News

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 05, 2026 | Analysis

Stay Connected